Santiago Palacios
ORCID: 0000-0003-2229-1200
· 6 papers in corpus
2026
The introduction of oral GnRH antagonists has created the possibility to replace progestins in combined oral contraceptives as the suppressor of ovarian function. A concept for this new approach to oral hormonal contraception is the combina…
article
2022
OBJECTIVE: To assess the improvement in vulvovaginal atrophy (VVA) of postmenopausal women treated with oral ospemifene 60 mg/day under conditions of routine clinical practice after 12 months of follow-up. METHODS: The AYSEX study is a Span…
2019
IntroductionApproximately 100 million women currently use combined oral contraceptives. Combined oral contraceptives use is associated with increased risk of venous thromboembolic events and cardiovascular disease. Progestin-only pills do n…
article
2013
OBJECTIVE: To summarise all clinical data on the contraceptive efficacy and bleeding profile associated with an oestradiol valerate (E2V) and dienogest (DNG) [E2V/DNG] combined oral contraceptive (COC) derived from Phase III trials. METHODS…
article
2009
ObjectiveA novel oral contraceptive (OC) that contains oestradiol valerate (E2V; 1 mg of E2V is equivalent to 0.76 mg of 17beta-oestradiol) and dienogest (DNG) has been developed. The efficacy and safety of this formulation was assessed in …
article
2005
We present a 44-year-old female patient who was being studied by the Gynecology Department because of the presence of large abdominal masses which proved to be leiomyomas on histological analysis. The Dermatology Department was consulted be…